Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
The Oncologist|April 6, 2024
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, et al.
Targeted Oncology|June 17, 2016
Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)Akihito Tsuji, Yu Sunakawa, Wataru Ichikawa, et al.
Clinical Colorectal Cancer|November 19, 2016
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 TrialsYu Sunakawa, Wataru Ichikawa, Akihito Tsuji, et al.
Cancer Science|April 3, 2008
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1Ken-ichi Fujita, Wataru Yamamoto, Shoji Endo, et al.
Cancer Chemotherapy and Pharmacology|October 20, 2010
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancerYu Sunakawa, Wataru Ichikawa, Ken-Ichi Fujita, et al.
Biological & Pharmaceutical Bulletin|November 5, 2008
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)Ken-ichi Fujita, Fumio Nagashima, Wataru Yamamoto, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 29, 2010
Delayed elimination of SN-38 in cancer patients with severe renal failureKen-ichi Fujita, Yu Sunakawa, Keisuke Miwa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 5, 2021
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07Yoshihiro Kakeji, Kazuhiro Yoshida, Yasuhiro Kodera, et al.
JCO Precision Oncology|January 20, 2022
RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal CancerYu Sunakawa, Masato Nakamura, Masahiro Ishizaki, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2009
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancerKen-ichi Fujita, Yuichi Ando, Wataru Yamamoto, et al.
Pageof 8